Status:
UNKNOWN
Study for Validation of Target Therapy in Multiple Myeloma Cells From Patients With miRNAs Released From B Cells, and Study of the Bone Marrow Tumor Microenvironment (Microenvironment of MM)
Lead Sponsor:
Centro di Riferimento Oncologico - Aviano
Conditions:
Multiple Myeloma
Eligibility:
All Genders
18+ years
Brief Summary
Multiple Myeloma (MM) is a hematologic cancer caused by the selective clonal expansion of plasma cells. By acting on the microenvironment of the bone marrow, MM shifts the niche balance and becomes ch...
Detailed Description
Multiple Myeloma (MM) is a hematologic cancer caused by the selective clonal expansion of plasma cells. By acting on the microenvironment of the bone marrow, MM shifts the niche balance and becomes ch...
Eligibility Criteria
Inclusion
- Age≥18 years;
- Diagnosis of multiple myeloma for which a bone marrow biopsy is scheduled for practice
- Patients able to express appropriate consent to participation in the study (e.g., able to understand Italian, patient with intact cognitive abilities).
Exclusion
- Absence of signed informed consent form
- Inadequate or insufficient bone marrow biopsy material
Key Trial Info
Start Date :
February 16 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
February 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT06154317
Start Date
February 16 2023
End Date
February 1 2025
Last Update
December 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Centro di Riferimento Oncologico (CRO) di Aviano - IRCCS
Aviano, Pordenone, Italy, 33081